Search results for "CARBOPLATIN"

showing 10 items of 81 documents

Outcome of peripheral blood stem cell mobilization in advanced phases of CML is dependent on the type of chemotherapy applied

1998

High-dose chemotherapy with autologous transplantation of in vivo purged PBSC is a novel investigational approach to treating chronic myelogenous leukemia (CML) patients not responsive to conventional therapy with interferon-alpha (IFN-alpha) and not eligible for allogeneic transplantation. PBSC mobilization using either '5+2/7+3'-type chemotherapy or 'mini-ICE/ ICE' chemotherapy was investigated in 43 patients with advanced phases of Philadelphia (Ph)-positive CML. Thirty patients were in late chronic phase (12 months post diagnosis) and 13 patients in accelerated phase (AP) or blast crisis (BC). Contamination with Ph-positive cells was evaluated in harvests from 37/43 patients. The outcom…

AdultOncologymedicine.medical_specialtyTime FactorsAllogeneic transplantationmedicine.medical_treatmentPilot ProjectsCarboplatinCohort StudiesLeukemia Myelogenous Chronic BCR-ABL PositiveInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAutologous transplantationIfosfamideEtoposideChemotherapyMobilizationHematologybusiness.industryHematologyGeneral MedicineLeukapheresisMiddle Agedmedicine.diseaseHematopoietic Stem Cell MobilizationSurgeryTreatment OutcomeBlast CrisisComplicationbusinessChronic myelogenous leukemiaAnnals of Hematology
researchProduct

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovaria…

2013

Summary Background In the Gynecologic Cancer Intergroup International Collaboration on Ovarian Neoplasms 7 (ICON7) trial, bevacizumab improved progression-free survival in patients with ovarian cancer when used in combination with first-line chemotherapy and as a single-drug continuation treatment for 18 cycles. In a preliminary analysis of a high-risk subset of patients, there was also an improvement in overall survival. This study aims to describe the health-related quality-of-life (QoL) outcomes from ICON7. Methods ICON7 is a randomised, multicentre, open-label phase 3 trial. Between Dec 18, 2006, and Feb 16, 2009, after a surgical procedure aiming to debulk the disease, women with Inter…

Adultmedicine.medical_specialtyBevacizumabDrug-Related Side Effects and Adverse ReactionsAntibodies Monoclonal HumanizedDisease-Free Survivallaw.inventionchemistry.chemical_compoundRandomized controlled trialQuality of lifelawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedNeoplasm StagingOvarian NeoplasmsIntention-to-treat analysisbusiness.industryStandard treatmentArticlesMiddle Agedmedicine.diseaseCarboplatinSurgeryBevacizumabClinical trialTreatment OutcomeOncologychemistryQuality of LifeFemaleOvarian cancerbusinessmedicine.drugThe Lancet Oncology
researchProduct

Apoptotic effects of different drugs on cultured retinoblastoma Y79 cells

1998

This paper deals with the apoptotic effect exerted in human retinoblastoma Y79 cells by a number of compounds. A remarkable effect was observed after treatment with DNA-damaging agents, such as camptothecin, etoposide, cisplatin and carboplatin; camptothecin was found to be the most efficacious. Treatment with these compounds induced the appearance of morphological features of apoptosis in the cells together with the distinct fragmentation of DNA, as shown by agarose gel electrophoresis. These effects were also accompanied by a remarkable increase in the level of p53. Many other compounds, which are not DNA-damaging agents, induced the morphological features of apoptosis but none of them we…

AmsacrinePaclitaxelDNA damageAntineoplastic AgentsApoptosisSuraminDNA ladderingBiologyretinoblastomaCarboplatinchemistry.chemical_compoundTumor Cells CulturedmedicineHumansFragmentation (cell biology)EtoposideCisplatinSodium butyrateGeneral MedicineAntineoplastic Agents PhytogenicMolecular biologyButyrateschemistryApoptosisAgarose gel electrophoresisImmunologyButyric AcidCamptothecinCisplatinDrug Screening Assays AntitumorCamptothecinDNA Damagemedicine.drug
researchProduct

Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour …

2016

Abstract Objective To establishing whether neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is superior primary debulking surgery (PDS) in terms of clinical outcome as well as peri-operative morbidity in advanced epithelial ovarian cancer (AEOC) endowed with high tumour load (HTL). Material and methods This is a single-Institution, superiority, randomised phase III trial enrolling supposed AEOC women. Patients considered pre-operatively eligible were triaged to staging laparoscopy to assess the predictive index (PI) of tumour load. All AEOC women with PI ≥ 8 or ≤ 12 (considered as HTL) were included. They were randomly assigned (1:1 ratio) to undergo either PDS f…

Cancer ResearchCarcinoma Ovarian EpithelialRandomised clinical trialCarboplatinCytoreductionchemistry.chemical_compoundPostoperative Complications0302 clinical medicineQuality of lifeAntineoplastic Combined Chemotherapy ProtocolsNeoplasms Glandular and EpithelialOvarian Neoplasms030219 obstetrics & reproductive medicineCytoreduction Surgical ProceduresMiddle AgedDebulkingOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemalemedicine.symptomAdultQuality of lifemedicine.medical_specialtyAdolescentPaclitaxelNauseaOperative TimeYoung Adult03 medical and health sciencesOvarian cancerBody ImagemedicineHumansProgression-free survivalAgedAnalysis of VarianceAdvanced ovarian cancer; Cytoreduction; Laparoscopy; Peri-operative complications; Quality of life; Randomised clinical trialbusiness.industryPeri-operative complicationsPerioperativeLength of StayCarboplatinSurgeryClinical trialSettore MED/40 - GINECOLOGIA E OSTETRICIAchemistryAdvanced ovarian cancerLaparoscopyPeri-operative complicationComplicationbusiness
researchProduct

Uncommon Synchronous Association between Ovarian Carcinoma and Gastrointestinal Stromal Tumor: A Case Study and Literature Review

2013

Background The association of gastrointestinal stromal tumors (GIST) and other cancers is well known, but its synchronous occurrence with gynecological malignancies is very uncommon. Usually, the diagnosis is accidentally established. We describe a patient with GIST and concurrent ovarian cancer and discuss the clinical implications of this finding. Case report A 64-year-old woman with a prior diagnosis of ovarian cancer developed a second recurrence after having undergone two operations and adjuvant chemotherapy. While tumor debulking was performed, a small, nonsuspicious lesion was removed from the greater curvature of the stomach. Histology revealed a GIST. Conclusion The association of …

Cancer ResearchPaclitaxelGastrointestinal Stromal TumorsOvariectomyAntigens CD34Carcinoma Ovarian EpithelialCystectomyHysterectomyCarboplatin030218 nuclear medicine & medical imagingNeoplasms Multiple PrimarySalpingectomy03 medical and health sciencesPancreatectomy0302 clinical medicineOvarian cancerSynchronous occurrenceStomach NeoplasmGastrectomyStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsGastrointestinal Stromal TumorBiomarkers TumorHumansNeoplasms Glandular and EpithelialColectomyOvarian NeoplasmsAntineoplastic Combined Chemotherapy ProtocolOvarian NeoplasmGeneral MedicineMiddle AgedImmunohistochemistryProto-Oncogene Proteins c-kitTreatment OutcomeOncologyChemotherapy AdjuvantCA-125 Antigen030220 oncology & carcinogenesisSplenectomyLymph Node ExcisionFemaleHumanTumori Journal
researchProduct

Activity of O(6)-methylguanine-DNA methyltransferase in relation to p53 status and therapeutic response in ovarian cancer.

1999

The DNA-repair protein O(6)-methylguanine-DNA methyltransferase (alkyltransferase; MGMT) is a major determinant of resistance of cells to various alkylating cytostatic drugs. Its expression in tissues is highly variable, indicating complex regulatory mechanisms involved. Transfection-mediated expression of wild-type p53 has been shown to negatively regulate basal promoter activity of MGMT in vitro. To elucidate whether p53 is involved in regulation of MGMT in tumor tissue, we examined MGMT expression and the p53 status of 140 primary ovarian carcinomas and analyzed the data as to the correlation between MGMT and p53, as well as the survival response of the patients after chemotherapy. We sh…

Cancer ResearchPathologymedicine.medical_specialtyMethyltransferaseTime FactorsCyclophosphamidemedicine.medical_treatmentBiologyDisease-Free Survivalchemistry.chemical_compoundO(6)-Methylguanine-DNA MethyltransferasePredictive Value of TestsmedicineHumansneoplasmsNeoplasm StagingRetrospective StudiesOvarian NeoplasmsChemotherapyL-Lactate DehydrogenaseCancermedicine.diseaseGenes p53ImmunohistochemistrySurvival Analysisdigestive system diseasesNitrogen mustardCarboplatinOncologychemistryCancer researchFemaleTumor Suppressor Protein p53Ovarian cancermedicine.drugAlkyltransferaseFollow-Up StudiesInternational journal of cancer
researchProduct

The apoptotic effects of cisplatin and carboplatin in retinoblastoma Y79 cells.

1998

This study demonstrated that cisplatin and carboplatin stimulate apoptosis in human retinoblastoma Y79 cells, cisplatin being the most effective compound. The apoptotic effect appeared after 8 h and then increased in a time-dependent manner. Treatment with cisplatin and carboplatin also provoked an increase in the level of p53 and p21, and a lowering in Bcl-2. The prolonged exposure of Y79 cells to cisplatin induced resistance to cisplatin, carboplatin and etoposide. The basal level of p53 was in resistant cells higher than in untreated cells, while Bcl-2 was not modified. p53 and Bcl-2 levels did not change after treating of resistant cells with cisplatin, carboplatin or etoposide. However…

Cancer ResearchProgrammed cell deathPathologymedicine.medical_specialtyCell Survivalmedicine.medical_treatmentAntineoplastic AgentsApoptosisBiologychemistry.chemical_compoundTumor Cells CulturedmedicineHumansEtoposideCisplatinChemotherapyRetinoblastomaDNA NeoplasmCarboplatinProto-Oncogene Proteins c-bcl-2OncologychemistryDrug Resistance NeoplasmApoptosisCell culturecarboplatinCancer researchCisplatinTumor Suppressor Protein p53Camptothecinmedicine.drugInternational Journal of Oncology
researchProduct

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced o…

2019

Purpose This study investigated the safety and clinical activity of lumretuzumab, a humanised antihuman epidermal growth factor receptor 3 (HER3) monoclonal antibody, in combination with carboplatin and paclitaxel in first-line treatment of patients with squamous non-small cell lung cancer (sqNSCLC). HER3 ligand heregulin and HER3 protein expression were evaluated as potential biomarkers of clinical activity. Patients and methods This open-label, phase Ib/II study enrolled patients receiving lumretuzumab at 800 mg (flat) in combination with carboplatin (area under the curve (AUC) 6 mg/mL×min) and paclitaxel (200 mg/m 2) administered intravenously on a every 3-week schedule. Adverse event (A…

Cancer Researchnon-small cell lung cancer (NSCLC)phase ilcsh:RC254-282chemistry.chemical_compoundErbB3heregulinMedicineERBB3Epidermal growth factor receptor1506squamousOriginal Researchbiologybusiness.industryArea under the curveLumretuzumabmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCarboplatinnon-small cell lung cancer (NSCLC)OncologychemistryPaclitaxelhuman epidermal growth factor receptor 3 (HER3)Cancer researchbiology.proteinNeuregulinbiomarkerbusinessESMO open
researchProduct

Endoplasmic reticulum stress is involved in response of human laryngeal carcinoma cells to carboplatin but is absent in carboplatin resistant cells

2013

The major obstacle of successful tumor treatment with carboplatin (CBP) is the development of drug resistance. In the present study, we found that following treatment with CBP the amount of platinum which enters the human laryngeal carcinoma (HEp2)-derived CBP- resistant (7T) cells is reduced relative to the parental HEp2. As a consequence, the formation of reactive oxidative species (ROS) is reduced, the induction of endoplasmic reticulum (ER) stress is diminished, the amount of inter- and intrastrand cross-links is lower, and the induction of apoptosis is depressed. In HEp2 cells, ROS scavenger tempol, inhibitor of ER stress salubrinal, as well as gene silencing of ER stress marker CCAAT/…

Celllcsh:MedicineApoptosisCarboplatinSalubrinalapoptosis; carboplatin; drug resistance; endoplasmic reticulum stress; reactive oxidative species; tumor cellschemistry.chemical_compound0302 clinical medicineBlotting Southwesternlcsh:Science0303 health sciencesMultidisciplinaryThioureaGeologyEndoplasmic Reticulum Stress3. Good healthmedicine.anatomical_structure030220 oncology & carcinogenesisSignal transductionSignal TransductionResearch ArticleProgrammed cell deathCell SurvivalBlotting WesternBiologyReal-Time Polymerase Chain ReactionCyclic N-Oxides03 medical and health sciencesCell Line TumormedicineHumansGene SilencingLaryngeal NeoplasmsBiology030304 developmental biologyDNA PrimersPlatinumEndoplasmic reticulumlcsh:RCarcinomaMolecular biologychemistryCell cultureApoptosisCinnamatesDrug Resistance NeoplasmUnfolded protein responseCancer researchlcsh:QSpin LabelsReactive Oxygen Species
researchProduct

Children <1 year show an inferior outcome when treated according to the traditional LGG treatment strategy: A report from the german multicenter t…

2013

Background Children diagnosed with LGG at an age <1 year are reported to have an impaired prognosis in comparison to older patients. Analysis of this subgroup could reveal the necessity to develop risk-adapted treatment approaches. Procedure Children <1 year at diagnosis (n = 66, median age 7.3 months, 33 female, none NFI) from the HIT-LGG 1996 cohort were analyzed for risk factors for EFS, PFS and OS. Several children suffered from diencephalic syndrome (DS, n = 22) and primary dissemination (DLGG, n = 9), 50 had a supratentorial midline (SML) location. Extent of resection was complete/subtotal in 12, partial in 15, biopsy in 27. Tumors were pilocytic astrocytoma WHO grade I (n = 33), othe…

ChemotherapyPediatricsmedicine.medical_specialtyPilocytic astrocytomamedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentBrachytherapyHematologymedicine.diseaseCarboplatinRadiation therapychemistry.chemical_compoundOncologychemistryMulticenter trialPediatrics Perinatology and Child HealthBiopsyCohortmedicinebusinessPediatric Blood &amp; Cancer
researchProduct